IP Library › Granted Patent US 12,343,420
Granted Patent B2
US 12,343,420 · App. 17/494,751 · Granted Jul 1, 2025

Stabilized polyribonucleotide coding for an elastic fibrous protein

Inventors: Hans-Peter Wendel (Balingen, DE); Timea Keller (Tuebingen, DE); Andrea Nolte (Deckenpfronn, DE); Meltem Avci-Adali (Kirchentellinsfurt, DE); Tobias Walker (Tuebingen, DE)
Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
A61K8/606A61K31/7115A61K48/005A61Q19/08C07K14/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,420
App. No.
17/494,751
Granted
Jul 1, 2025
Kind
B2
Abstract

The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.

Claims (22)

1. A method for the induction of the synthesis of elastic fibrous protein in an organism, comprising the following steps:

(1) providing a polyribonucleotide, and

(2) administering said polyribonucleotide in or to cells of an organism to synthesize elastin/tropoelastin in said cells,

wherein said polyribonucleotide encodes elastin/tropoelastin and comprises at least two polyribonucleotide stabilizing chemical modifications, wherein at least approximately 25% to 50% of the uridines of the polyribonucleotide are replaced by pseudouridines (Ψ) and at least approximately 25% to 50% of the cytidines of the polyribonucleotide are replaced by 5-methylcytidines (m5C) to stabilize the polyribonucleotide; and

wherein level of synthesized elastin/tropoelastin in said cells is approximately sixfold to tenfold as compared to level of synthesized elastin/tropoelastin in cells to which unmodified polyribonucleotide encoding elastin/tropoelastin is administered.

2. The method of claim 1 , wherein said polyribonucleotide is an mRNA.

3. The method of claim 1 , wherein said polyribonucleotide further comprises a chemically modified uridine selected from the group consisting of: 5-methyluridine, 5-idouridine, 4-thiouridine, 5-bromouridine, 2′-methyl-2′-deoxyuridine, 2′-amino-2′-deoxyuridine, 2′-azido-2′-deoxyuridine, 2′-fluoro-2′-deoxyuridine, and combinations thereof.

4. The method of claim 1 , wherein said polyribonucleotide further comprises a chemically modified cytidine selected from the group consisting of 5-methylcytidine, 3-methylcytidine, 2-thiocytidine, 2′-methyl-2′-deoxcytidin, 2′-amino-2′-deoxycytidine, 2′-fluoro-2′-deoxycytidine, 5-iodcytidine, 5-bromocytidine, and 2′-azido-2′-deoxycytidine, and combinations thereof.

5. The method of claim 4 , wherein said polyribonucleotide further comprises a chemical modification selected from the group consisting of: a 5′ cap structure, a poly (A) tail, a cap structure analog, and a strengthening of a translation-initiation sequence at the start codon AUG by the sequence (CCCCGC)aucGagAUG.

6. The method of claim 1 , wherein said polyribonucleotide comprises the sequence of SEQ ID NO:1, wherein at least approximately 25% of the uridines of the polyribonucleotide are replaced by pseudouridines and at least approximately 25% of the cytidines of the polyribonucleotide are replaced by 5-methylcytidines.

7. The method of claim 1 , wherein said polyribonucleotide encodes an amino acid sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.

8. The method of claim 1 , wherein said polyribonucleotide is configured for any of the following indications: the induction of the synthesis of elastin/tropoelastin, in age-related loss of elasticity of the skin (wrinkle formation), for promoting wound healing, and for the recovery of the elasticity of vaginal tissue, soft and hard tissue of the periodontium.

9. The method of claim 1 , wherein said polyribonucleotide is configured for the treatment of a deficient synthesis of elastin/tropoelastin.

10. The method of claim 1 , wherein said polyribonucleotide is configured for the treatment of a disease selected from the group consisting of: arteriosclerosis, aortic stenosis, aortic aneurysm, pulmonary emphysema, dermatochalasis, Williams-Beuren syndrome, and sub valvular innate aortic stenosis (SVAS).

11. The method of claim 1 , wherein said polyribonucleotide is provided in a pharmaceutically acceptable formulation.

12. The method of claim 1 , wherein said polyribonucleotide is provided in a cosmetically acceptable formulation.

13. The method of claim 1 , wherein the level of synthesized elastin/tropoelastin in the cells is approximately tenfold as compared to level of synthesized elastin/tropoelastin in cells to which unmodified polyribonucleotide encoding elastin/tropoelastin is administered.

14. The method of claim 1 , wherein in said polyribonucleotide approximately 25% of the uridines of the polyribonucleotide are replaced by pseudouridines (Ψ) and approximately 25% of the cytidines of the polyribonucleotide are replaced by 5-methylcytidines (m5C).

15. The method of claim 1 , wherein in addition an immune-suppressive agent is administered in or to said organism.

16. The method of claim 1 , wherein the polyribonucleotide encodes an amino acid sequence selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.

17. The method of claim 1 , wherein the polyribonucleotide encodes an amino acid sequence selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, and which composition is configured to cause a lower level of IL-6 activation as compared to a level of IL-6 activation caused by a comparable amount of the immunostimulant polyinosinic/polycytidylic acid.

18. The method of claim 1 , wherein said polyribonucleotide is provided as comprised by a medical patch or a vascular implant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: WENDELL, HANS-PETER; KELLER, TIMEA; NOLTE, ANDREA; AVCI-ADALI, MELTEM; WALKER, TOBIAS
To: EBERHARD-KARLS-UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
Reel/Frame 064985/0242 →
Priority Claims (1)
DE 102013005361.7 · Mar 28, 2013 · national
Continuity (3)
Continuation 14868259 · Sep 28, 2015
Continuation PCTEP2014056233 · Mar 27, 2014
Related Publication 20220249346A1 · Aug 11, 2022
References Cited (56)
US 7074596B2 · Darzynkiewicz · 2006 [cited by applicant]
US 8288347B2 · Collette · 2012 [cited by examiner]
US 20090093433A1 · Woolf et al. · 2009 [cited by applicant]
US 20120195936A1 · Rudolph et al. · 2012 [cited by applicant]
US 20120251618A1 · Schrum et al. · 2012 [cited by applicant]
WO WO2007024708A2 · 2007 [cited by examiner]
WO 2008052770A2 · 2008 [cited by applicant]
WO 2008067195A2 · 2008 [cited by applicant]
WO 2008100789A2 · 2008 [cited by applicant]
WO 2009127230A1 · 2009 [cited by applicant]
WO 2011008904A1 · 2011 [cited by applicant]
WO 2011012316A2 · 2011 [cited by applicant]
WO 2012019168A2 · 2012 [cited by applicant]
WO 2012045075A1 · 2012 [cited by applicant]
WO 2012045082A2 · 2012 [cited by applicant]
WO 2012135805A2 · 2012 [cited by applicant]
WO 2012158736A1 · 2012 [cited by applicant]
WO 2014154844A1 · 2014 [cited by applicant]
AMA Style Insider (Sep. 2012) downloaded from Around, About, Approximately | AMA Style Insider on May 9, 2023. [cited by examiner]
E.insights (Jun. 2014) downloaded from https://www.editage.com/insights/scientific-writing-difference-in-meaning-of-about-around-and-approximately on May 9, 2023. [cited by examiner]
Kormann et al. (Nature Biotechnology, 2011 vol. 29:154-157). [cited by examiner]
GenBank Accession No. BC035570 (Mar. 4, 2003). [cited by examiner]
Prabhakar et al. (Journal of Drug Delivery & Therapeutics; 2013, 3:213-221). [cited by examiner]
Warren et al. (Cell Stem Cell, 2010 vol. 7:618-630). [cited by examiner]
Non-Final Rejection for U.S. Appl. No. 14/868,259, dated Jan. 31, 2017, 11 pages. [cited by applicant]
Amendment in Response to Non-Final Office Action under 37 C.F.R. 1.111 for U.S. Appl. No. 14/868,259, dated Jun. 30, 2017, 15 pages. [cited by applicant]
Final Rejection for for U.S. Appl. No. 14/868,259, dated Oct. 12, 2017, 18 pages. [cited by applicant]
Application Initiated Interview Summary for U.S. Appl. No. 14/868,259, dated Feb. 26, 2018, 3 pages. [cited by applicant]
Application Summary of Interview with Examiner for U.S. Appl. No. 14/868,259, dated Feb. 27, 2018, 2 pages. [cited by applicant]
Request Continue Exam and Amendment in Response to FOA under 37 C.F.R. 1.116 for U.S. Appl. No. 14/868,259, dated Apr. 10, 2018, 18 pages. [cited by applicant]
Affidavit-Traversing Rejections or Objections Rule 132 for U.S. Appl. No. 14/868,259, dated Apr. 10, 2018, 6 pages. [cited by applicant]
Non-Final Rejection for U.S. Appl. No. 14/868,259, dated Apr. 26, 2018, 20 pages. [cited by applicant]
Amendment in Response to Final Office Action under 37 C.F.R. 1.111 for U.S. Appl. No. 14/868,259, dated Sep. 25, 2018, 18 pages. [cited by applicant]
Final Rejection for U.S. Appl. No. 14/868,259, dated Dec. 27, 2018, 19 pages. [cited by applicant]
Amendment in Response to Final Office Action under 37 C.F.R. 1.116 for U.S. Appl. No. 14/868,259, dated Jun. 26, 2019, 10 pages. [cited by applicant]
Non-Final Rejection for U.S. Appl. No. 14/868,259, dated Aug. 13, 2018, 14 pages. [cited by applicant]
Amendment in Response to Non-Final Office Action under 37 C.F.R. 1.111 for U.S. Appl. No. 14/868,259, dated Jan. 13, 2020, 10 pages. [cited by applicant]
Final Rejection for U.S. Appl. No. 14/868,259, dated Feb. 27, 2020, 12 pages. [cited by applicant]
Amendment in Response to Final Office Action under 37 C.F.R. 1.116 for U.S. Appl. No. 14/868,259, dated Jun. 26, 2020, 20 pages. [cited by applicant]
Non-Final Rejection for U.S. Appl. No. 14/868,259, dated Aug. 11, 2020, 19 pages. [cited by applicant]
Response to Non-Final Action under 37 C.F.R. 1.111 for U.S. Appl. No. 14/868,259, dated Feb. 8, 2021, 28 pages. [cited by applicant]
Final Rejection for U.S. Appl. No. 14/868,259, dated May 5, 2021, 21 pages. [cited by applicant]
Abandonment for U.S. Appl. No. 14/868,259, dated Nov. 15, 2021, 2 pages. [cited by applicant]
AMA Style Insider. Around, About, Approximately. Downloaded on Oct. 4, 2017 from http://amastyleinsider.com/2012/09/14/around-about-approximately/. [cited by applicant]
David Wolman. Natural Healing. (MIT Technology Reviews, Biomedicine, Jun. 21, 2005), pp. 1-6, downloaded from https://www.technologyreview.com/s/404312/natural-healing/on Jan. 26, 2017. [cited by applicant]
GenBank Accession No. BC035570, Submitted (Jul. 31, 2002) National Institutes of Health, Mammalian Institute, 31 Center Drive, Room 11 A03, Bethesda, MD 20892-2590, USA. [cited by applicant]
Hirano et al. “Functional rescue of elastin insufficiency in mice by the human elastin gene: implications for mouse models of human disease,” Circulation Research (2007) 101:523-531. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2014/056233, dated Jul. 14, 2014, 32 pages. [cited by applicant]
Internet Search HGNC ID: HHGNC 3327. Retrieved from http://www.genenames.org/cgibin/gene_symbol_report?hgnc_id=HGNC:3327 Retrieved in 2013. [cited by applicant]
Kormann et al. “Expression of therapeutic proteins after delivery of chemically mRNA in mice,” Nature Biotechnology (2011) 29(2):154-159. [cited by applicant]
Mandal et al. “Reprogramming human fibroblasts to pluripotency using modified mRNA,” Nature Protocals (2013) 8:568-582. [cited by applicant]
NCBI—Elastin isoform protein sequence. Downloaded from https://www.ncbi.nlm.nih.gov/protein/126352440 on Apr. 12, 2018. [cited by applicant]
Nolte et al. (Mol. Med. 2011 vol. 17:1213-1222). [cited by applicant]
Scientific writing: Difference in meaning of “About,” “Around,” and “Approximately” by Yateendra Joshi. Jun. 12, 2014. Downloaded from https ://www. editag.com/insights/scientific-writing-difference-in-meaning-of-about-… [cited by applicant]
Warren et al. “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA,” Cell Stem Cell (2010) 7:618-630. [cited by applicant]
Xiong et al., “Elastic fibers reconstructed using adenovirus-mediated expression of tropoelastin and tested in the elastase model of abdominal aortic aneurysm in rate,” J Vasc Surg (2008) 48(4):965-973. [cited by applicant]